Douglas Jay Weckstein
52 works · 2,998 citations · h-index 25
Top works
- Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
- Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
- Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
- Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer
- The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro.
- Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
- Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
- Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
- Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer
- PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
- Assessment of Perceived Cost to the Patient and Other Barriers to Clinical Trial Participation
- Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
- CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.